Evidence (7631 claims)
Adoption
8570 claims
Productivity
7631 claims
Governance
6869 claims
Human-AI Collaboration
6491 claims
Org Design
4175 claims
Innovation
4114 claims
Labor Markets
3566 claims
Skills & Training
2966 claims
Inequality
2066 claims
Evidence Matrix
Claim counts by outcome category and direction of finding.
| Outcome | Positive | Negative | Mixed | Null | Total |
|---|---|---|---|---|---|
| Other | 758 | 199 | 100 | 900 | 2007 |
| Governance & Regulation | 826 | 400 | 191 | 122 | 1563 |
| Organizational Efficiency | 777 | 193 | 124 | 84 | 1189 |
| Technology Adoption Rate | 635 | 233 | 124 | 97 | 1098 |
| Research Productivity | 422 | 128 | 57 | 336 | 954 |
| Output Quality | 476 | 179 | 59 | 47 | 761 |
| Decision Quality | 328 | 177 | 81 | 47 | 640 |
| Firm Productivity | 435 | 57 | 88 | 20 | 606 |
| AI Safety & Ethics | 218 | 277 | 65 | 33 | 599 |
| Market Structure | 180 | 170 | 123 | 24 | 502 |
| Task Allocation | 213 | 64 | 72 | 33 | 387 |
| Skill Acquisition | 170 | 61 | 61 | 17 | 309 |
| Innovation Output | 203 | 27 | 43 | 18 | 292 |
| Employment Level | 105 | 54 | 107 | 13 | 281 |
| Fiscal & Macroeconomic | 131 | 69 | 43 | 26 | 276 |
| Consumer Welfare | 117 | 63 | 42 | 11 | 233 |
| Firm Revenue | 153 | 48 | 26 | 3 | 230 |
| Task Completion Time | 173 | 31 | 8 | 12 | 225 |
| Inequality Measures | 44 | 122 | 49 | 6 | 221 |
| Worker Satisfaction | 89 | 65 | 22 | 12 | 188 |
| Error Rate | 69 | 92 | 10 | 2 | 173 |
| Regulatory Compliance | 77 | 69 | 14 | 5 | 165 |
| Automation Exposure | 56 | 56 | 26 | 13 | 154 |
| Training Effectiveness | 94 | 21 | 13 | 19 | 149 |
| Wages & Compensation | 77 | 36 | 25 | 6 | 144 |
| Team Performance | 86 | 17 | 27 | 10 | 141 |
| Developer Productivity | 95 | 17 | 14 | 6 | 133 |
| Job Displacement | 12 | 80 | 20 | 1 | 113 |
| Hiring & Recruitment | 52 | 7 | 8 | 3 | 70 |
| Creative Output | 31 | 18 | 8 | 3 | 61 |
| Skill Obsolescence | 5 | 46 | 6 | 1 | 58 |
| Social Protection | 27 | 16 | 8 | 2 | 53 |
| Labor Share of Income | 17 | 19 | 17 | — | 53 |
| Worker Turnover | 11 | 12 | — | 3 | 26 |
| Industry | — | — | — | 1 | 1 |
Productivity
Remove filter
Integration points for AI across the imaging pathway include acquisition (image quality/protocol selection), triage (prioritization), interpretation/reporting (detection, quantification, report pre-population), and post-interpretation (teaching, QA, model improvement loops).
Descriptive synthesis of reported implementations and proposed use cases in the literature and deployment reports across multiple institutions.
Human-AI collaboration can produce synergistic gains (diagnostic complementarity) when errors are uncorrelated and tasks are allocated to leverage comparative strengths.
Theoretical/analytical models of error complementarity and empirical reader studies showing instances where combined readings outperform either agent alone (evidence drawn from multiple small-to-moderate reader studies and simulations).
AI in radiology has clear potential to improve diagnostic performance and workflow efficiency.
Narrative synthesis of laboratory evaluation studies, reader/comparison studies, and a limited number of observational deployment reports showing improved algorithm accuracy and some improvements in measured throughput or time-to-review in pilots (study sizes and settings heterogeneous; few large-scale RCTs).
Cognitive Shadow supports real-time model updates based on immediate user feedback, enabling iterative improvement and continuous alignment with human decision patterns.
Described human-in-the-loop interaction loop where CS captures human decisions, provides recommendations, receives immediate feedback, and updates models dynamically in the simulation environment (implementation detail).
HACL/CS reduces omission rates (missed detections) in the simulated scenarios.
Omission/error rates were tracked and compared between conditions in the simulated testbed; summary claims reduction in omissions with HACL assistance but does not report numeric effect sizes or significance.
HACL/CS reduces time-to-decision in the simulated maritime surveillance tasks.
Measured time-to-classify in simulation under human-alone vs HACL-assisted conditions; summary indicates reductions in time-to-decision but lacks detailed statistics in the provided description.
In the simulated Canadian Arctic maritime surveillance domain, HACL/CS shows promise for improving classification accuracy.
Performance comparison between human-alone and HACL-assisted conditions in the maritime surveillance simulation measuring classification accuracy; summary reports improvement but does not provide sample size or significance levels.
Adjustable autonomy via self-confidence thresholds enables the system to act autonomously on high-certainty predictions and defer to humans on low-certainty cases.
System design feature of Cognitive Shadow implemented in simulation: autonomy decision rule based on meta-model confidence thresholds; behavior demonstrated in human-in-the-loop scenarios.
The Cognitive Shadow toolkit quantifies AI reliability with an empirical (0–1) confidence metric produced by a recursive meta-model.
Design and implementation detail: primary supervised models are paired with a recursive meta-model that predicts the primary model's reliability per situation and outputs a 0–1 empirical confidence score; applied in the simulated testbed.
Implementing an adaptive command-and-control process augmented by AI metacognition (the Cognitive Shadow toolkit) aligns AI judgments with expert human decision patterns.
Cognitive Shadow (CS) implemented as supervised ML models trained to mimic expert human decisions in the simulated maritime scenarios; alignment assessed by comparing model outputs to human expert decisions during human-in-the-loop interaction (implementation validated in simulation).
Human-AI co-learning (HACL) improves human-autonomy teaming (HAT) effectiveness.
Evaluated in a simulated Canadian Arctic maritime surveillance testbed using human-in-the-loop experiments comparing human-alone vs HACL-assisted conditions; exact participant sample size and statistical details not provided in the summary.
Self-directed autonomous agents (those that autonomously generated prompts and selected tools) bypassed human prompting failures and outperformed most human teams on the challenge set.
Comparative analysis of the four autonomous agents' trajectories, tool use, and success rates versus the 41 human participants/teams on the same fresh challenges; observed correlation between autonomous self-direction and higher success relative to most teams.
Clinical-interface validation with real physicians on mobile devices confirmed the practical viability and usability of the HADT system and interface.
Paper reports an interface test with real doctors using the mobile interface as part of validation (number of physicians, tasks, and quantitative usability metrics not specified in the summary).
On public datasets HADT achieves superior accuracy/human-effort trade-offs compared to baselines (fully human, fully automated, and simpler assignment strategies).
Comparative evaluations reported in the paper on public medical-consultation datasets (baselines listed broadly; exact baseline implementations, dataset names, and quantitative comparisons not included in the provided summary).
The execution machine uses masked hierarchical reinforcement learning with bottom-up training to ask informative symptom questions from a large symptom space.
Methodological description and reported training procedure in the paper (bottom-up training applied to the execution module; claimed to improve question selection; experimental validation referenced but details not provided in the summary).
A two-layer hierarchical reinforcement learning system—an assignment 'master' and an execution 'machine' (plus human doctors)—effectively balances accuracy and human cost.
Architectural design and experimental evaluation in the paper demonstrating trade-offs between diagnostic accuracy and human involvement using the hierarchical RL setup (experiments run on public datasets; exact sample sizes not given).
The Human-AI Diagnostic Team (HADT) framework can deliver near-expert-level online symptom inquiry and diagnosis while using very little human labor.
Performance reported on public datasets and clinical-interface tests with real physicians; described comparisons to expert-level performance in the paper's main finding (specific comparative statistics to experts not provided in the summary).
HADT reached up to 89.4% diagnostic accuracy while requiring only 10.9% human effort.
Empirical results reported in the paper from experiments on public online medical-consultation datasets and clinical-interface validation with real doctors (dataset names and sample sizes not specified in the provided summary).
HR and organizational implication: Firms should consider emotional dynamics when designing hybrid teams; training, monitoring, and pairing strategies (human–human, human–AI) matter for short-term task performance.
Interpretation by authors based on experimental findings that emotion and perceived service empathy alter collaboration proficiency across partner types in temporary virtual tasks (n = 861).
Design implication: Investing in AI features that convey empathy or supportive social cues could increase collaboration proficiency when emotion matters.
Authors' inference grounded in mediation (service empathy → collaboration proficiency) and the partner-type moderation of that effect in the experiment (n = 861), suggesting empathy-signaling features could alter outcomes.
Findings are consistent with the 'computers are social actors' (CASA) framework: people respond to computers as social actors, so social/affective cues (not just whether a partner is human) shape collaboration outcomes.
Theoretical interpretation offered by the authors, supported by empirical patterns in the experiment (significant moderation by emotion and mediation by service empathy despite no main effect of partner type).
AI-mediated collaboration will create new organizational roles and governance structures, such as AI mediators and verification/oversight roles.
Conceptual discussion of organizational implications and illustrative role examples; no organizational case studies with sample sizes reported.
Autonomous AI agents can automate routine coordination tasks, follow-up, and some task execution, thereby reducing human coordination overhead.
Paper uses conceptual mapping of agent capabilities to coordination/execution functions and provides illustrative case scenarios; no experimental or field data presented.
Multimodal systems (integrating text, speech, images, video) broaden communication channels and thus can improve the range and fidelity of mediated communication.
Conceptual argument and illustrative examples in the paper describing how multimodal integration maps to communication functions; no empirical validation reported.
Multilingual language models reduce language barriers by translating and normalizing meaning across languages.
Conceptual synthesis of capabilities (multilingual LMs) and mapping to coordination function (translation/normalization); supported in paper by illustrative examples rather than empirical testing.
Trust in AI should be conceptualized as a socio-technical, team-level mechanism (trust calibration) that mediates between AI design/enablers and downstream collaboration and performance, rather than an individual-level stable attitude.
Theoretical synthesis combining findings from the thematic analysis of 40 interviews with socio-technical systems theory (STS) and adaptive structuration theory (AST) to propose an initial and revised conceptual model linking enablers → trust-calibration practices → collaboration dynamics → performance.
Five enablers support effective trust calibration: transparency/explainability, clear role definitions, good user experience (UX), supportive cultural norms, and timely system feedback.
Synthesized from recurring themes in the interview data (N=40) where respondents identified these factors as facilitating appropriate reliance on AI in project settings; coded and aggregated through thematic analysis.
Performance and reward structures must be redesigned to value oversight, hypothesis testing, escalation and governance behaviours that mitigate model risk but may not immediately increase output.
Managerial recommendation derived from the framework and organizational reward literature; no empirical evaluation provided.
Firms need new metrics to decompose value created by humans, AI, and their interaction (to distinguish complementarities versus substitution).
Analytic implication derived from the framework and literature on productivity measurement; presented as a recommendation for empirical work rather than tested evidence.
Symbiarchic leadership is a practical, HR‑oriented framework for leading integrated human–AI “cyber teams,” specifying four linked leadership practices that make AI a co‑actor in knowledge work while preserving human judgement, accountability and organizational legitimacy.
Paper's central proposition based on theoretical synthesis of academic literature on human–AI collaboration, hybrid teams and digital‑era leadership plus illustrative practitioner examples; no original empirical data or experiments.
Policies improving data sharing, standardization, and model transparency would increase overall welfare by reducing duplication and improving model performance.
Policy argumentation in the paper drawing on economic theory and examples where shared datasets/standards improved research productivity.
Organizations that tightly integrate AI teams with experimental groups achieve higher productivity.
Case studies and internal metrics cited in the paper showing improved throughput and candidate progression in integrated teams versus siloed approaches.
Value accrues to firms that control high-quality data, integrated platforms, and wet-lab validation—data and experimental capacity are strategic assets.
Market and organizational analysis in the paper citing examples of firms leveraging proprietary data/platforms and wet-lab capabilities to advance candidates more effectively.
AI reduces time and cost in early-stage discovery (discovery-to-candidate), lowering per-candidate screening and design costs.
Reported case studies and cost/time comparisons in the paper showing faster candidate identification and reduced experimental burden in early stages; aggregated industry claims summarized.
Several AI-guided molecules have entered clinical trials and show encouraging early-phase indicators.
Industry reports and trial registries summarized in the paper reporting multiple AI-guided programs reaching Phase I/II; company disclosures and early-phase biomarker or safety readouts referenced.
Recommendations for policy include investing in public data infrastructure and standards, promoting regulatory clarity for AI validation, and supporting equitable access to AI-driven innovations.
Policy recommendations derived from synthesis of challenges and potential remedies presented in the narrative review; based on conceptual policy analysis and examples rather than empirical testing of interventions.
Policies that incentivize interoperable, privacy-preserving data sharing (e.g., federated data, common standards) can reduce entry barriers and improve social returns from AI in drug R&D.
Policy analysis and recommendations from the review, supported by conceptual arguments and examples of federated/privacy-preserving platforms; limited empirical validation of large-scale impact.
AI has the potential to raise R&D productivity by shortening timelines and reducing certain failure modes, thereby increasing the net present value (NPV) of successful drug projects.
Economic reasoning and projections based on documented process improvements in the reviewed studies and reports; not validated by longitudinal, generalized financial analyses in the literature.
AI enhances post-market safety signal detection using real-world data analytics.
Industry and regulatory reports and published studies in the review documenting improved detection or earlier identification of safety signals in pharmacovigilance applications using ML on real-world datasets.
AI-enabled adaptive and enrichment trial designs increase trial efficiency and statistical power.
Methodological studies, clinical-trial case studies, and regulatory guidance summarized in the review showing applications of ML to adaptive/enrichment designs; evidence mainly illustrative and context-specific.
AI improves predictive toxicity and ADMET models, which can reduce late-stage failures.
Multiple empirical studies and industry case reports aggregated in the narrative review demonstrating improved in silico toxicity/ADMET prediction performance in specific settings; heterogeneity across datasets and endpoints; not a formal meta-analysis.
AI can reduce time-to-market and lower some drug development costs.
Synthesis of case studies, industry reports, and empirical studies reported in the narrative review that document examples of compressed timelines and cost savings in parts of the pipeline; review notes lack of long-run, generalized ROI estimates.
AI is materially accelerating discovery and development steps in pharmaceutical R&D, improving target identification, lead optimization, safety prediction, and adaptive trial design.
Narrative review synthesizing published studies, review articles, industry and regulatory reports; evidence primarily consists of empirical studies and case studies covering preclinical and clinical-stage applications. No pooled quantitative meta-analysis; heterogeneous methods and therapeutic areas.
Firms with superior proprietary data and integration capability gain competitive advantage, increasing firm-level heterogeneity in AI returns.
Narrative analysis of market structure implications and examples; no cross-firm empirical heterogeneity study included.
Returns to complementary investments (data infrastructure, experiment automation, cross-disciplinary teams) increase as AI becomes more central to discovery workflows.
Synthesis of adoption lessons and case examples emphasizing complementary capital; no quantitative ROI estimates provided.
Embedding AI into organizational processes, decision-making, and wet-lab validation is crucial to capturing its value.
Narrative review of adoption and integration lessons from large biopharma experience and illustrative case studies.
Successful AI adoption requires investment in data, talent, and workflows rather than reliance on bolt-on point solutions.
Thematic analysis of adoption-level lessons and industry case examples indicating organizational and infrastructural requirements for realized value.
AI has produced genuine early-stage breakthroughs in drug discovery, accelerating hit identification and early design cycles.
Narrative expert synthesis and thematic analysis of industry experience over the first decade of AI adoption, illustrated by early-case successes and firm-reported accelerations; no new primary experimental data or causal econometric estimates provided.
Public policies that lower frictions for secure data sharing, standardize validation metrics, and support workforce retraining can accelerate beneficial diffusion of AI while managing risks.
Policy recommendation based on the paper's synthesis of enablers and constraints; not empirically tested within the paper.
AI has the potential to reduce marginal cost and time per candidate (shorter design loops, in silico screening), increasing effective productivity of R&D spend if improvements are validated.
Theoretical and conceptual argument referencing capabilities of generative models and simulation; paper states no new quantitative estimates were produced.